Korean pharmaceutical Boryung said Thursday its line of hypertension drugs, coined the “Kanarb family,” recorded 5.18 billion won ($4.6 million) in prescription sales in September, elevating the drug to potential blockbuster status.

Boryung’s line of fimasartan products – Kanarb, Kanarb Plus, Dukarb, and Tuvero – showed high performance in local and overseas markets becoming a leading example of a successful new drug, the company said.

The Kanarb family demonstrated rapid blood pressure-lowering effects through the largest clinical trial in the country involving about 37,000 people, Boryung said, noting continual presentation of clinical evidence has helped in establishing the drugs in the medical field.

The company also exported its hypertension drugs to Russia, China, Africa and Latin America, recording export worth $474.6 million since 2011. Efforts to invest in research and development for value-added pipelines and expanding domestic and overseas markets have helped, the company noted.

“The Kanarb products are the newest ARB antihypertensive therapies that demonstrated a strong, sustained blood pressure-lowering effect for up to 24 hours,” a company official said. “The drug increases the number of treatment options while improving patient’s quality of life.”

Boryung is also developing other fimasartan combination products along with a hypertension-diabetes combination therapy that combines Kanarb and Trajenta, the company said.